BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ADL5945: Phase II data

Top-line data from the double-blind, U.S. Phase II Study 242 trial in 131 chronic non-cancer pain patients with OIC showed that twice-daily 0.25 mg ADL5945 met the primary endpoint of significantly increasing the weekly average number of SBMs from baseline to week 4 vs. placebo (3.4 vs. 1.4 SBMs per week, p=0.0003). The twice-daily 0.1...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >